AbbVie Inc.
ABBV
$167.29
-$0.51-0.30%
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | -5.42% | -5.97% | -4.92% | -9.70% | 1.58% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -5.42% | -5.97% | -4.92% | -9.70% | 1.58% |
| Cost of Revenue | 3.41% | 29.35% | 1.54% | -1.22% | 34.22% |
| Gross Profit | -8.75% | -23.97% | -7.49% | -13.28% | -6.94% |
| SG&A Expenses | 14.53% | 2.93% | 1.91% | 4.16% | -1.02% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 100.00% | -- | -- | -- | -101.47% |
| Total Operating Expenses | 8.14% | 17.09% | 2.79% | 10.36% | 11.39% |
| Operating Income | -25.46% | -50.83% | -16.82% | -41.69% | -10.12% |
| Income Before Tax | -59.12% | -55.61% | 120.63% | -90.36% | -30.58% |
| Income Tax Expenses | -21.30% | -61.61% | 128.63% | -46.33% | 118.14% |
| Earnings from Continuing Operations | -66.67% | -54.93% | 118.43% | -94.64% | -38.89% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -300.00% | 0.00% | 25.00% | 33.33% | 200.00% |
| Net Income | -66.76% | -54.98% | 119.05% | -94.68% | -38.85% |
| EBIT | -25.46% | -50.83% | -16.82% | -41.69% | -10.12% |
| EBITDA | -19.79% | -34.93% | -9.72% | -28.90% | -5.80% |
| EPS Basic | -66.95% | -54.95% | 120.86% | -94.91% | -38.80% |
| Normalized Basic EPS | -25.38% | -54.29% | -14.85% | -45.00% | -8.84% |
| EPS Diluted | -66.95% | -54.75% | 123.37% | -94.89% | -38.76% |
| Normalized Diluted EPS | -25.38% | -54.27% | -14.76% | -44.95% | -8.84% |
| Average Basic Shares Outstanding | -0.34% | -0.23% | -0.17% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | -0.34% | -0.28% | -0.28% | -0.11% | 0.00% |
| Dividend Per Share | 4.73% | 4.96% | 4.96% | 4.96% | 4.96% |
| Payout Ratio | 2.15% | 1.33% | -0.52% | 18.79% | 0.77% |
